Comparison of the APTIMA® HIV-1 Quant Assay to the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0

A. Hatzakis, H. Papachristou, M. Kantzanou; Dept of Hygiene, Epidemiology & Medical Statistics, University of Athens Medical School, Athens, Greece.

Abstract

Background: The APTIMA HIV-1 Quant Assay is a fully automated quantitative assay being developed on the PANTHER System and based on real-time Transcription-Mediated Amplification technology. This assay is intended for monitoring HIV-1 viral load in plasma specimens using as low as 0.5 mL sample.

Method:

A cohort of 245 clinical specimens from University of Athens Medical School was tested using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 (Roche Assay) and the APTIMA HIV-1 Quant Assay (APTIMA Assay). The specimens included subtypes A, B, C and G as well as circulating recombinant forms of HIV-1.

Results:

Using an lower limit of quantitation for the APTIMA Assay of 30 copies/mL, 175 specimens gave results quantifiable for both assays. The correlation between the two assays was excellent (0.98), with a slope of 1.06 and an intercept of 0.13. Sixty-nine samples gave results that were either detectable but not quantifiable or not detectable in at least one assay. Thirty were not detectable in both assays and 14 were detectable in both assays. The APTIMA Assay detected 13 specimens that were undetectable with the Roche Assay.

Conclusion:

The APTIMA HIV-1 Quant Assay gave comparable viral load results when compared to the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0. The sensitivity of the APTIMA HIV-1 Quant Assay is similar to that of the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0.

Method Comparison

A cohort of 245 clinical specimens was tested using the Roche Assay and the APTIMA Assay. The APTIMA Assay results were generated at Gen-Probe. The Roche results were generated at the University of Athens. The results are shown as scatter plots in Figures 4 and 5 for those samples giving quantitative results in both assays.

Figure 4. Comparison of APTIMA and Roche Assays using All Clinical Sample Data

Figure 5. Comparison of APTIMA and Roche Assays using Subtype B Clinical Sample Data

Assay Procedure

The APTIMA Quantitative Assay Reagents and plasma samples are loaded into the PANTHER System (Figure 1) and sample bays (Figure 2).

The PANTHER System processes 0.5 mL of samples through target capture, amplification, and real-time detection in the presence of an internal control.

The assay has 1 negative control and two positive controls (1 low and 1 high concentration).

KEY FEATURES OF PANTHER SYSTEM

- Full automation from sample to result
- Random sample loading eliminating the need for batching samples together to perform the assay
- Continuous access to change reagents, samples, and consumables
- Small instrument footprint
- 2.5 hrs to first result
- <50 tests results in 4.5 hours
- <50 test results in <11 hours

Figure 1. PANTHER System

Figure 2. PANTHER Reagent and Sample bay

Assay Technology

Target Capture

Transcription-Mediated Amplification

Real-time Signal Generation

Sensitivity

Sixty-nine specimens gave results that were either detectable but not quantifiable or not detectable in at least one assay. The results are shown on Table 2. Samples with detectable results were designated as positive and those whose target was not detected designated negative for the assay used.

Table 2. Comparison of Clinical Samples using the APTIMA and Roche HIV Assays

| IU/mL | Instrument 1 | Instrument 2 | Average | N | Positive minimal | Probitanalysis of data estimated sensitivity at which the APTIMA HIV-1 Quant Assay detects | 95% of samples is 17.8IU/mL (IU is approximately 1 copy). |
|-------|--------------|--------------|---------|---|-----------------|------------------------------------------------------------------------------------------|
| 0     | -            | +            | N9      |   | 0.0%            | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |
| 5     | 90.0%        | 90.0%        | 90.0%   |   | 90.0%           | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |
| 10    | 90.0%        | 90.0%        | 90.0%   |   | 90.0%           | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |
| 15    | 90.0%        | 90.0%        | 90.0%   |   | 90.0%           | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |
| 20    | 90.0%        | 90.0%        | 90.0%   |   | 90.0%           | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |
| 25    | 90.0%        | 90.0%        | 90.0%   |   | 90.0%           | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |
| 30    | 90.0%        | 90.0%        | 90.0%   |   | 90.0%           | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |
| 40    | 90.0%        | 90.0%        | 90.0%   |   | 90.0%           | 95% of samples is 17.8IU/mL (IU is approximately 1 copy).                                |

Conclusions

The APTIMA HIV-1 Quant Assay gave comparable viral load results when compared to the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0. The sensitivity of the APTIMA HIV-1 Quant Assay is similar to that of the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0.

The APTIMA HIV-1 Quantitative assay is a good candidate for monitoring HIV-1 viral load in HIV-1 infected patients.

APTIMA and PANTHER are trademarks of Gen-Probe Incorporated. Table 1 was published with the permission of Gen-Probe. COBAS is a trademark of Roche Diagnostics Operations, Inc. Taqman is a trademark of Roche Molecular Systems, Inc.